News

Tyra Biosciences Unveils Promising Preclinical Data for TYRA-300

Tyra Biosciences Unveils Promising Preclinical Data for TYRA-300

Tyra Biosciences' Exciting Announcement at ENDO 2025

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company, has made a significant stride in the field of precision medicine. They announced a highly anticipated late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025). This event is set to occur shortly, and it underscores Tyra's commitment to advancing treatments that target critical opportunities in Fibroblast Growth Factor Receptor (FGFR) biology.

Details of the Poster Presentation

The poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," promises to shed light on groundbreaking research. The presenting author, Dr. Jacqueline H. Starrett from Tyra Biosciences, will delve into the innovative findings that illustrate the positive impact of TYRA-300 on bone growth, a vital aspect of treating related conditions.

Presentation Information

Here are the critical details regarding the presentation at ENDO 2025:

  • Abstract: SUN-730
  • Date/Time: July 13, with the presentation scheduled from 12:00 PM to 1:30 PM
  • Location: ENDOExpo, Poster Area
  • Session: P70 - BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders

About TYRA-300

At the heart of Tyra Biosciences’ innovation is TYRA-300, an investigational drug developed through their proprietary SNÅP platform, specifically designed as an oral, FGFR3-selective inhibitor. This drug is at the forefront of the company's pipeline and has exhibited promising interim clinical proof-of-concept results in metastatic urothelial cancer (mUC). The comprehensive development of TYRA-300 includes three Phase 2 clinical trials: SURF302 targeting intermediate risk non-muscle invasive bladder cancer (IR NMIBC), BEACH301 for pediatric achondroplasia, and SURF301 aimed at mUC. Each trial represents a step towards enhancing treatment options for various patient populations.

Carrying Forward the Promise of Precision Medicine

Tyra Biosciences continuously seeks to provide advanced healthcare solutions that improve patients' lives. TYRA-300 is positioned to be a potential first-in-class selective FGFR3 inhibitor that avoids the common toxicities associated with the inhibition of other FGFR subtypes, making it a groundbreaking therapeutic candidate. Such innovations exemplify the company's dedication to addressing significant medical needs.

Further Information About Tyra Biosciences

Tyra Biosciences specializes in developing cutting-edge precision medicines that leverage advancements in FGFR biology. The company’s innovative SNÅP platform plays a crucial role, allowing rapid drug design through iterative molecular snapshots aimed at overcoming genetic resistance to existing therapies. Tyra’s pipeline, featuring TYRA-300 among others, includes targeted programs that stand to revolutionize treatment protocols in oncology and genetically defined conditions.

In addition to TYRA-300, the company is also progressing with other investigational drugs, including TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral FGFR4/3-biased inhibitor for cancers driven by FGF19 and FGFR4. Each of these development programs reflects Tyra's commitment to advancing the science of biomedicine in the ongoing fight against cancer and other serious diseases.

Frequently Asked Questions

What is TYRA-300?

TYRA-300 is an investigational oral FGFR3-selective inhibitor developed by Tyra Biosciences for treating various conditions including cancer.

When is the poster presentation scheduled?

The poster presentation will take place on July 13, during the ENDO 2025 conference.

Who will present the findings on TYRA-300?

Dr. Jacqueline H. Starrett will present the findings related to TYRA-300.

What are the ongoing trials for TYRA-300?

TYRA-300 is currently involved in three Phase 2 clinical trials focusing on bladder cancer, pediatric conditions, and metastatic urothelial cancer.

How does Tyra Biosciences contribute to precision medicine?

Tyra Biosciences utilizes its innovative SNÅP platform to design precise drugs targeting genetic alterations, enhancing the efficacy of treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 95

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 39

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 86

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 39

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 138

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 125

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 125

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 144

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading

Top 5 Most Recently Viewed Articles

The Exclusion of XRP from Trump's Crypto Reserve Explained

Updated Category News Views 679

Understanding the Strategic Crypto Reserve Exclusion The cryptocurrency world was recently shaken when President Donald Trump issued an executive order that left notable omissions. Among these was XRP, a digital asset that Ripple and its supporters had hoped to see included in a U.S. sovereign crypto reserve. The Ripple Effects of Trump's Order After investing heavily in...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 168

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Zillow Unveils Innovative AI Virtual Staging for Listings

Updated Category News Views 283

Zillow Introduces AI-Powered Virtual Staging In an exciting development for real estate, Zillow has recently launched an innovative feature known as Virtual Staging. This tool harnesses the power of artificial intelligence to enhance how listings are showcased, making the home-buying experience even more engaging for potential buyers. Creating a Visual Experience for Home...

Continue Reading
Balchem Corporation: Innovating Health and Nutrition Solutions

Updated Category News Views 296

Balchem Corporation's Upcoming Conference Presentation Balchem Corporation, a prominent global manufacturer known for its specialty ingredients aimed at health and nutrition markets, is set to make a significant presentation at an upcoming virtual conference. The CJS Securities New Ideas for the New Year Virtual Conference will feature notable company figures, including...

Continue Reading
Projected Growth of Cottonseed Oilseed Processing Market

Updated Category News Views 85

Overview of Cottonseed Oilseed Processing Market Growth The cottonseed oilseed processing market is experiencing significant growth, projected to reach $7.7 billion within a decade, showcasing a compound annual growth rate (CAGR) of 6.8%. The increasing demand for vegetable oils, primarily for their versatility and cost-effectiveness, plays a crucial role in this market's...

Continue Reading